Cormark Weighs in on Cipher Pharmaceuticals Inc.’s Q1 2017 Earnings (CPHR)
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR) – Cormark dropped their Q1 2017 earnings estimates for Cipher Pharmaceuticals in a report released on Monday. Cormark analyst D. Novak now anticipates that the brokerage will post earnings per share of $0.05 for the quarter, down from their prior estimate of $0.08. Cormark also issued estimates for Cipher Pharmaceuticals’ Q2 2017 earnings at $0.03 EPS, Q3 2017 earnings at $0.06 EPS, Q4 2017 earnings at $0.03 EPS and FY2017 earnings at $0.17 EPS.
A number of other brokerages have also weighed in on CPHR. TD Securities restated a “buy” rating and issued a $7.50 price objective on shares of Cipher Pharmaceuticals in a report on Saturday, August 13th. GMP Securities restated a “hold” rating on shares of Cipher Pharmaceuticals in a report on Saturday, August 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $6.85.
Shares of Cipher Pharmaceuticals (NASDAQ:CPHR) opened at 3.879 on Tuesday. The stock’s market cap is $101.61 million. Cipher Pharmaceuticals has a 12 month low of $3.55 and a 12 month high of $6.37. The company has a 50 day moving average price of $4.03 and a 200-day moving average price of $5.09.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
Receive News & Stock Ratings for Cipher Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.